Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29262873 | 0.99 | ADRB2 (0.36) | ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL5045815 | 0.98 | ADRB2 (0.34) | ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL313294 | 0.96 | ADRB2 (0.32) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5049088 | 0.87 | POLB (0.31) | — | |
| SCHEMBL2729756 | 0.86 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL5049182 | 0.85 | — | — | |
| SCHEMBL23483313 | 0.84 | — | — | |
| SCHEMBL9656868 | 0.84 | — | — | |
| SCHEMBL16995921 | 0.84 | — | — | |
| SCHEMBL238099 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392640-B1 | CYCLOALKANECARBOXYLIC ACID DERIVATIVES AS FRAGRANTS WITH MUSK CHARACTERISTICS | GIVAUDAN SA (CH) | 2007-12-19 | — | — | EP | claimed |
| US-20040234568-A1 | Cycloalkanecarboxylic acid derivatives as fragants with musk characteristics | GIVAUDAN SA (CH) | 2004-11-25 | — | — | US | claimed |
| EP-1392640-A1 | CYCLOALKANECARBOXYLIC ACID DERIVATIVES AS FRAGRANTS WITH MUSK CHARACTERISTICS | Givaudan SA (CH) | 2004-03-03 | — | — | EP | claimed |
| WO-2002096852-A1 | CYCLOALKANECARBOXYLIC ACID DERIVATIVES AS FRAGRANTS WITH MUSK CHARACTERISTICS | GIVAUDAN SA (CH) | 2002-12-05 | — | — | WO | claimed |
| EP-1262474-A1 | Cycloalkanecarboxylic acid derivatives as fragrants with musk characteristics | Givaudan SA (CH) | 2002-12-04 | — | — | EP | claimed |
| US-7390779-B2 | Cycloalkanecarboxylic acid derivatives as fragants with musk characteristics | GIVAUDAN SA (CH) | 2008-06-24 | — | — | US | disclosed |
| EP-1392640-B1 | CYCLOALKANECARBOXYLIC ACID DERIVATIVES AS FRAGRANTS WITH MUSK CHARACTERISTICS | GIVAUDAN SA (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20040234568-A1 | Cycloalkanecarboxylic acid derivatives as fragants with musk characteristics | GIVAUDAN SA (CH) | 2004-11-25 | — | — | US | disclosed |
| EP-1392640-A1 | CYCLOALKANECARBOXYLIC ACID DERIVATIVES AS FRAGRANTS WITH MUSK CHARACTERISTICS | Givaudan SA (CH) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002096852-A1 | CYCLOALKANECARBOXYLIC ACID DERIVATIVES AS FRAGRANTS WITH MUSK CHARACTERISTICS | GIVAUDAN SA (CH) | 2002-12-05 | — | — | WO | disclosed |
| EP-1262474-A1 | Cycloalkanecarboxylic acid derivatives as fragrants with musk characteristics | Givaudan SA (CH) | 2002-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234568-A1 | Cycloalkanecarboxylic acid derivatives as fragants with musk characteristics | FASN, ACMSD, CMPK1 | ADRB2 1350/4885ADRB1 1260/4885ADRB3 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.